Search results
Showing 1 to 15 of 113 results for bladder cancer
This guideline covers diagnosing and managing bladder cancer in people 18 and above referred from primary care with suspected bladder cancer, and those with newly diagnosed or recurrent bladder (urothelial carcinoma, adenocarcinoma, squamous-cell carcinoma or small-cell carcinoma) or urethral cancer.
This quality standard covers diagnosing and managing bladder cancer in adults (aged 18 and over) referred from primary care. It describes high-quality care in priority areas for improvement.
View quality statements for QS106Show all sections
Sections for QS106
- Quality statements
- Quality statement 1: Obtaining detrusor muscle during transurethral resection of bladder tumour
- Quality statement 2: Chemotherapy during transurethral resection of bladder tumour
- Quality statement 3: Access to a clinical nurse specialist
- Quality statement 4: Risk classification
- Quality statement 5: Discussing treatment options for high-risk non-muscle-invasive bladder cancer
- Quality statement 6: Discussing treatment options for muscle-invasive urothelial bladder cancer
- Quality statement 7: Discharge to primary care
All NICE products on bladder cancer. Includes any guidance, advice and quality standards.
Bladder EpiCheck for the detection of bladder cancer recurrence (MT706)
Topic prioritisation
Topic prioritisation
In development Reference number: GID-TA11694 Expected publication date: 10 February 2027
In development Reference number: GID-NG10452 Expected publication date: TBC
Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for neoadjuvant treatment and then alone for adjuvant treatment of muscle-invasive bladder cancer in adults.
Evidence-based recommendations on Synergo for non-muscle-invasive bladder cancer.
In development Reference number: GID-TA11767 Expected publication date: 04 November 2026
Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (HTG522)
Evidence-based recommendations on transurethral laser ablation for recurrent non-muscle-invasive bladder cancer in adults. This involves using a laser inserted into the bladder to destroy the cancer cells.
View recommendations for HTG522Show all sections
Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer (HTG487)
Evidence-based recommendations on intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer in adults. This involves using microwaves to improve the effect of the chemotherapy given directly into the bladder.
View recommendations for HTG487Show all sections
Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer (HTG499)
Evidence-based recommendations on electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer in adults. This involves using a small electrical current to improve the effect of chemotherapy given directly into the bladder.
View recommendations for HTG499Show all sections
Bladder EpiCheck for detecting bladder cancer recurrence (MIB293)
NICE has developed a medtech innovation briefing (MIB) on Bladder EpiCheck for detecting bladder cancer recurrence .